GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiromic BioPharma Inc (OTCPK:KRBP) » Definitions » Operating Margin %

Kiromic BioPharma (Kiromic BioPharma) Operating Margin % : 0.00% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Kiromic BioPharma Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Kiromic BioPharma's Operating Income for the three months ended in Mar. 2024 was $-5.11 Mil. Kiromic BioPharma's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Kiromic BioPharma's Operating Margin % for the quarter that ended in Mar. 2024 was 0.00%.

The historical rank and industry rank for Kiromic BioPharma's Operating Margin % or its related term are showing as below:


KRBP's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -158.97
* Ranked among companies with meaningful Operating Margin % only.

Kiromic BioPharma's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Kiromic BioPharma's Operating Income for the three months ended in Mar. 2024 was $-5.11 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-20.28 Mil.

Warning Sign:

Kiromic BioPharma Inc has never been profitable in the past 3 years. It lost money every year.


Kiromic BioPharma Operating Margin % Historical Data

The historical data trend for Kiromic BioPharma's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiromic BioPharma Operating Margin % Chart

Kiromic BioPharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial - - - - -

Kiromic BioPharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Kiromic BioPharma's Operating Margin %

For the Biotechnology subindustry, Kiromic BioPharma's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kiromic BioPharma's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiromic BioPharma's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Kiromic BioPharma's Operating Margin % falls into.



Kiromic BioPharma Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Kiromic BioPharma's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-19.939 / 0
= %

Kiromic BioPharma's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=-5.113 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kiromic BioPharma  (OTCPK:KRBP) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Kiromic BioPharma Operating Margin % Related Terms

Thank you for viewing the detailed overview of Kiromic BioPharma's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Kiromic BioPharma (Kiromic BioPharma) Business Description

Traded in Other Exchanges
N/A
Address
7707 Fannin Street, Suite 140, Houston, TX, USA, 77054
Kiromic BioPharma Inc is a biotechnology company. It is an artificial intelligence (AI) driven, end-to-end allogeneic cell therapy company, currently developing the multi-indication allogeneic T cell therapy that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company is a gene-editing which utilizes artificial intelligence and a proprietary neural network platform with a therapeutic focus on immuno-oncology.
Executives
Brian Hungerford officer: CFO 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Pamela Misajon director 7707 FANNIN ST, SUITE 140, HOUSTON TX 77054
Michael Catlin director 7707 FANNIN ST, SUITE 140, HOUSTON TX 77054
Karen Reeves director 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Francis X Tirelli director 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Daniel Grant Clark officer: Interim CFO 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Internati Maurizio Chiriva director, officer: Chairman, CEO, and President 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Michael Charles Ryan officer: Chief Technology Officer 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Ignacio Nunez officer: See Remarks 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Jerry A. Schneider director ONE VISION DRIVE, NATICK MA 01760
Michael Nagel director C/O VASCULAR SOLUTIONS INC, 6464 SYCAMORE COURT NORTH, MINNEAPOLIS MN 55369
Pietro Bersani director C/O FUEL SYSTEMS SOLUTIONS, INC., 780 THIRD AVE. 25TH FLOOR, NEW YORK NY 10017
Scott Dahlbeck officer: Chief Medical Officer 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Americo Cicchetti director 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Gianluca Rotino director, officer: CSIO 7707 FANNIN, SUITE 140, HOUSTON TX 77054

Kiromic BioPharma (Kiromic BioPharma) Headlines

From GuruFocus